FindTrial
Sign In

LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-508101-24-00
Acronym
UKM17_0023
Enrollment
544
Registered
2024-04-09
Start date
2019-08-01
Completion date
Unknown
Last updated
2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoblastic lymphoma

Brief summary

Primary endpoints of randomization 1: For the randomized question 1 the cumulative incidence of relapse with involvement of the CNS (CNS-relapse, pCICR) is the primary endpoint., Primary endpoints of randomization 2: For the randomized question 2 the estimated probability of event-free survival (pEFS) is the primary endpoint.

Interventions

DRUGDOXORUBICIN
DRUGDAUNORUBICIN
DRUGCYTARABINE
DRUGMETHOTREXATE
DRUGPREDNISONE
DRUGTIOGUANINE
DRUGMERCAPTOPURINE
DRUGCYCLOPHOSPHAMIDE
DRUGVINCRISTINE
DRUGDEXAMETHASONE
DRUGIFOSFAMIDE
DRUGVINDESINE
DRUGPEGASPARGASE
DRUGPREDNISOLONE

Sponsors

Universitaetsklinikum Muenster AöR
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Primary endpoints of randomization 1: For the randomized question 1 the cumulative incidence of relapse with involvement of the CNS (CNS-relapse, pCICR) is the primary endpoint., Primary endpoints of randomization 2: For the randomized question 2 the estimated probability of event-free survival (pEFS) is the primary endpoint.—

Countries

Austria, Belgium, Czechia, Denmark, Finland, Germany, Hungary, Italy, Netherlands, Norway, Poland, Slovakia, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026